Headspace Announces “Headspace Health,” Its New Digital Medicine Subsidiary | Business Wire

SANTA MONICA, Calif.–(BUSINESS WIRE)–Headspace,

a global leader in mindfulness and meditation, today announced the

formation of Headspace

Health, a new, wholly-owned subsidiary that'll pioneer new ways to

incorporate the Headspace meditation experience into digital medicine.

The new company plans to deliver the world’s first prescription

meditation app in 2020 when it anticipates the introduction of the first

product in its portfolio of newly developed, clinically-validated and

FDA-cleared meditation programs specifically designed to treat a broad

range of chronic diseases.

“The creation of Headspace Health is the most significant step ever

taken to introduce meditation into medicine at scale,” said Headspace

Co-Founder and CEO, Rich Pierson. “Health professionals have long

recommended Headspace as an effective tool in treating a wide variety of

health problems. Now we’re leading the effort to validate and

deliver prescription meditation solutions to doctors and their patients

for physical conditions. By standardizing meditation into health care,

we’re bringing Headspace even closer to realizing our mission of

improving health and happiness around the world.”

In summer 2018, Headspace Health is scheduled to begin Randomized

Controlled Trials (RCTs) on its first targeted disease state, to be

announced in the coming months. The completion of clinical trials and

subsequent FDA submission are scheduled for 2020, with the goal of

making Headspace Health’s initial prescription meditation program

available to doctors as an important tool in improving patient health

outcomes and quality of life.

Since 2015, Headspace has completed or is currently conducting more than

65 evidence-based research studies on the favourable health implications

of the Headspace meditation platform on clinical conditions such as

asthma and cancer, as well as future exploration in areas such as sleep

and pain management. Results to-date remain overwhelmingly positive as

to the material benefits of meditation on health and happiness across

both physical and mental conditions. Under the direction of Headspace

Chief Science Officer Dr. Megan Jones-Bell, these studies have been

primarily conducted in collaboration with third party partners, such as

the U.K.’s National Health Service (NHS), Kaiser Permanente, University

of Southern California Keck School of Medicine, Harvard University,

Stanford University, Carnegie Mellon, University of California San

Francisco. University of Texas Health Science Centre, San Antonio,

among other prestigious academic and research institutions.

“Since its inception, Headspace has maintained an in-house science team,

reinforcing our company’s long-standing commitment to academic research

and collaboration with clinicians,” said Dr. Jones Bell. “Over the last

few years, we’ve increasingly directed time and resources towards

expanding our scientific research pipeline and given the promising

results we’ve seen over that period, the next logical step was to make a

significant investment in the healthcare space through Headspace Health.”

Headspace Health will be led by Managing Director Dr. Joe Powers, a

20-year veteran of the digital health space, who'll report directly to

Dr. Jones-Bell.

“When our Co-Founders Andy Puddicombe and Rich Pierson first conceived

of Headspace, their initial vision involved normalizing meditation into

medicine,” Dr. Powers said. “With the formation of Headspace Health,

we’re realizing Andy and Rich’s goal of making meditation a

scientifically-proven form of treatment for health care providers and

platforms everywhere, giving us the opportunity to have a profound

impact on the health and well-being of millions worldwide.”

About Headspace Health

Established in 2018, Headspace

Health, a wholly-owned subsidiary of Headspace, is pioneering new

ways to incorporate the innovative Headspace meditation experience into

digital medicine. The company plans to deliver the world’s first

prescription meditation app to health professionals and their patients

in 2020, when it anticipates the introduction of the first product in

its portfolio of newly developed, clinically-validated and FDA-cleared

meditation programs specifically designed to treat a broad range of

chronic diseases.

About Headspace

Headspace, a global leader in meditation and mindfulness, was founded in

2010 by Andy Puddicombe and Rich Pierson with the goal of improving

health and happiness around the world. Through its core suite of

meditation app and online offerings, Headspace has already reached

nearly 30 million users in 190 countries. The company also operates a

B2B business focused on offering its meditation products to companies

everywhere as part of employee benefits packages. A partnerships

team that's forged robust relationships with many of the world’s most

recognisable brands, including Apple, Amazon, Google, Nike, the NBA and

more. For more information please visit us at www.headspace.com,

or follow us on Facebook, Twitter and Instagram.

Headspace
Steven Clark, 424-581-5106
[email protected]